Journal article · 2026 · Open access
Advancing Clinical Trials and Precision Medicine in Duchenne Muscular Dystrophy Using Machine Learning‐Based Trajectory Modeling and MRI Radiomics
Clinical Pharmacology & Therapeutics · Published 11 November 2026 · DOI 10.1002/cpt.70558
In brief
“Advancing Clinical Trials and Precision Medicine in Duchenne Muscular Dystrophy Using Machine Learning‐Based Trajectory Modeling and MRI Radiomics” is a 2026 journal article by Hyun-Jae Jeong and 7 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 0 citations as of 18 November 2026. It is open access: the full text is free to read at Clinical Pharmacology & Therapeutics.
- Citations
- 0
- References
- 36
- Authors
- 8
Abstract
Given heterogeneous progression of Duchenne muscular dystrophy (DMD), accurately characterizing individual disease trajectories is critical for effective clinical trials and therapeutic development. In this study, we applied machine learning (ML) approaches leveraging disease progression models and baseline magnetic resonance (MR)‐derived radiomic features to quantify individual‐level DMD progression trajectories and support quantitative characterization of disease progression. Radiomic features were extracted from segmented soleus (SOL) and vastus lateralis (VL) fat‐fraction maps, generating 810 features per individual, with additional functional and demographic measures incorporated as covariates following feature selection. Multiple ML regressors were trained and validated to estimate MR‐spectroscopy fat‐fraction trajectory descriptive parameters: DPT 50 (age at half‐maximal increase), DP max (extent), γ (rate), S 0 (extrapolated measure at age 0). Key radiomic features were identified through feature importance analyses, followed by downstream analyses, including unsupervised clustering. The tree‐based XGBoost regression model demonstrated best future longitudinal fat‐fraction trajectories (SOL: mean absolute error (MAE) = 0.04, R 2 = 0.94; VL: MAE = 0.06, R 2 = 0.95). Subsequent downstream analyses highlighted potential key biomarkers clinically associated with DMD progression. Clustering analysis revealed clinically meaningful slow‐ and fast‐progression subgroups with interpretable decision criteria (SOL: DPT 50 = 12.21 vs. 14.83; γ = 8.07 vs. 7.54, VL: 10.37 vs. 14.21; γ = 7.72 vs. 7.09) that can inform clinical trial designs and therapeutic effects within homogenous groups. Individual‐level feature importance interpretation further shows the possibility of tailoring personalized intervention strategies. These findings highlight the potential of ML‐based trajectory modeling approaches leveraging baseline MRI radiomics for advancing AI‐assisted clinical trial development and precision medicine, charting a new direction for MRI‐guided disease modeling in neuromuscular disorders.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Jeong, H.-J., Willcocks, R. J., Walter, G. A., Mueller, R. A., Sanabria, F. M., Triplett, W. T., Vandenborne, K., & Kim, S. (2026). Advancing Clinical Trials and Precision Medicine in Duchenne Muscular Dystrophy Using Machine Learning‐Based Trajectory Modeling and MRI Radiomics. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70558
MLA 9
Jeong, Hyun-Jae, et al. “Advancing Clinical Trials and Precision Medicine in Duchenne Muscular Dystrophy Using Machine Learning‐Based Trajectory Modeling and MRI Radiomics.” Clinical Pharmacology & Therapeutics, 2026. https://doi.org/10.1002/cpt.70558.
Chicago
Jeong, Hyun-Jae, Rebecca J. Willcocks, Glenn A. Walter, Robert A. Mueller, Fiorella M. Sanabria, William T. Triplett, Krista Vandenborne, and Sarah Kim. 2026. “Advancing Clinical Trials and Precision Medicine in Duchenne Muscular Dystrophy Using Machine Learning‐Based Trajectory Modeling and MRI Radiomics.” Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70558.
Harvard
Jeong, H.-J. et al. (2026) ‘Advancing Clinical Trials and Precision Medicine in Duchenne Muscular Dystrophy Using Machine Learning‐Based Trajectory Modeling and MRI Radiomics’, Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.70558.
IEEE
H.-J. Jeong et al., “Advancing Clinical Trials and Precision Medicine in Duchenne Muscular Dystrophy Using Machine Learning‐Based Trajectory Modeling and MRI Radiomics,” Clinical Pharmacology & Therapeutics, 2026, doi: 10.1002/cpt.70558.
BibTeX
@article{jeong2026advancing,
title = {{Advancing Clinical Trials and Precision Medicine in Duchenne Muscular Dystrophy Using Machine Learning‐Based Trajectory Modeling and MRI Radiomics}},
author = {Jeong, Hyun-Jae and Willcocks, Rebecca J. and Walter, Glenn A. and Mueller, Robert A. and Sanabria, Fiorella M. and Triplett, William T. and Vandenborne, Krista and Kim, Sarah},
journal = {Clinical Pharmacology \& Therapeutics},
year = {2026},
doi = {10.1002/cpt.70558},
url = {https://doi.org/10.1002/cpt.70558}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Duchenne muscular dystrophy
- disease progression modeling
- MRI radiomics
- fat fraction
- soleus muscle
- vastus lateralis
- XGBoost regression
- trajectory modeling
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Jeong, H.-J., Willcocks, R. J., Walter, G. A., Mueller, R. A., Sanabria, F. M., Triplett, W. T., Vandenborne, K., & Kim, S. (2026). Advancing Clinical Trials and Precision Medicine in Duchenne Muscular Dystrophy Using Machine Learning‐Based Trajectory Modeling and MRI Radiomics. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70558
How many times has this paper been cited?
0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.
Who wrote this paper?
Hyun-Jae Jeong, Rebecca J. Willcocks, Glenn A. Walter, Robert A. Mueller, Fiorella M. Sanabria, William T. Triplett, Krista Vandenborne, Sarah Kim.
What is the DOI of this paper?
10.1002/cpt.70558, permanently at https://doi.org/10.1002/cpt.70558. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.